The U.S. Food and Drug Administration approved a drug by the name of Xeljanz (tofacitinib) for patients who have an insufficient or allergic response to methotrexate, as treatment for fiercely active rheumatoid arthritis. Rheumatoid arthritis (RA) is an autoimmune disease, in which the body's healthy tissue is under attack by the immune system...

Read more...